Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Claggett

Showing results (141-150 of 361) with videos related to

Pageof 37
Sort By:
Clinical and Translational Gastroenterology|December 15, 2012
Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel diseaseJean-Francois Turcotte, Karen Wong, Stephanie J Mah, et al.
JACC. Heart Failure|November 15, 2020
Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HFKarola S Jering, Faiez Zannad, Brian Claggett, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 28, 2026
Left ventricular remodeling and diastolic dysfunction predict cognitive decline in older adultsArshama Dehghan, Fernando R Giugni, Katja Vu Bartholdy, et al.
The New England Journal of Medicine|January 1, 2015
The amyloidogenic V122I transthyretin variant in elderly black AmericansC Cristina Quarta, Joel N Buxbaum, Amil M Shah, et al.
JAMA Cardiology|October 10, 2019
Longitudinal Associations Between Income Changes and Incident Cardiovascular Disease: The Atherosclerosis Risk in Communities StudyStephen Y Wang, Andy S L Tan, Brian Claggett, et al.
European Journal of Heart Failure|September 19, 2018
The frailty syndrome and outcomes in the TOPCAT trialNatalie A Sanders, Mark A Supiano, Eldrin F Lewis, et al.
JAMA Cardiology|November 15, 2016
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF TrialAkshay S Desai, Orly Vardeny, Brian Claggett, et al.
JACC. Heart Failure|February 4, 2022
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HFPeder L Myhre, Margaret F Prescott, Sean P Murphy, et al.
European Journal of Heart Failure|June 11, 2021
Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trialKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
JAMA Network Open|January 23, 2023
Measures of Food Inadequacy and Cardiovascular Disease Risk in Black Individuals in the US From the Jackson Heart StudyRani Zierath, Brian Claggett, Michael E Hall, et al.
Pageof 37

Showing results (141-150 of 361) with videos related to

Sort By:
Pageof 37
Clinical and Translational Gastroenterology|December 15, 2012
Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel diseaseJean-Francois Turcotte, Karen Wong, Stephanie J Mah, et al.
JACC. Heart Failure|November 15, 2020
Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HFKarola S Jering, Faiez Zannad, Brian Claggett, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 28, 2026
Left ventricular remodeling and diastolic dysfunction predict cognitive decline in older adultsArshama Dehghan, Fernando R Giugni, Katja Vu Bartholdy, et al.
The New England Journal of Medicine|January 1, 2015
The amyloidogenic V122I transthyretin variant in elderly black AmericansC Cristina Quarta, Joel N Buxbaum, Amil M Shah, et al.
JAMA Cardiology|October 10, 2019
Longitudinal Associations Between Income Changes and Incident Cardiovascular Disease: The Atherosclerosis Risk in Communities StudyStephen Y Wang, Andy S L Tan, Brian Claggett, et al.
European Journal of Heart Failure|September 19, 2018
The frailty syndrome and outcomes in the TOPCAT trialNatalie A Sanders, Mark A Supiano, Eldrin F Lewis, et al.
JAMA Cardiology|November 15, 2016
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF TrialAkshay S Desai, Orly Vardeny, Brian Claggett, et al.
JACC. Heart Failure|February 4, 2022
Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HFPeder L Myhre, Margaret F Prescott, Sean P Murphy, et al.
European Journal of Heart Failure|June 11, 2021
Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trialKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
JAMA Network Open|January 23, 2023
Measures of Food Inadequacy and Cardiovascular Disease Risk in Black Individuals in the US From the Jackson Heart StudyRani Zierath, Brian Claggett, Michael E Hall, et al.
Pageof 37